1. Both glucagon (93 nM) and N8,O2'-dibutyryl cyclic adenosine 3' : 5'-phosphate (Bu,Ado-3' : 5'-P) (10 pM) stimulated gluconeogenesis from pyruvate to the extent of 35 in the perfused liver from fasted rats. Under these conditions, all of the pyruvate disappearance could be accounted for in lactate and glucose. When livers were perfused with pyruvate only, a portion of the pyruvate metabolized was unaccounted for, and presumably oxidized.2. Bu,Ado-3' : 5'-P, even in the presence of glycodiazine, stimulated gluconeogenesis from pyruvate and lowered the ratio of C, uptake to glucose ratio, suggesting a "sparing effect" on pyruvate oxidation.3. (+)-Decanoylcarnitine (0.5 mM) blocked a significant portion of the stimulation of gluconeogenesis by glucagon (93 nM). Other parameters of pyruvate metabolism were unaltered by the carnitine ester in the presence of glucagon. I n contrast, Bu,Ado-3' : 5'-P (10 pM) in the presence of ( + )-decanoylcarnitine significantly increased glucose formation in comparison to livers perfused only with the carnitine derivative. 4. Pentenoic acid (1 .O mM) resulted in a 50°/, inhibition of gluconeogenesis, a lowered pyruvate disappearance and an increase of pyruvate unaccounted for and presumably oxidized. Livers perfused with 4-pentenoic acid in addition to glucagon exhibited a marked suppression of gluconeogenesis, a decreased conversion of pyruvate to lactate and a lowered pyruvate disappearance rate. 5. Livers perfused with Bu,Ado-3' : 5'-P (10 pM) in addition to 4-pentenoic acid, when compared to livers perfused with 4-pentenoic acid, exhibited a significantly increased rate of gluconeogenesis. Bu,-Ado-3' : 5'-P exerted a "sparing effect" on pyruvate carbon even in the presence of 4-pentenoic acid.Although the mechanism of action of fatty acid on gluconeogenesis is not yet understood in detail, it seems well established that intermediates arising from fatty acid oxidation are responsible for the stimulation of glucose synthesis. This is underlined by the findings from other laboratories where inhibitors of fatty acid oxidation such as a-bromopalmitate [l]